Zoetis
About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Employees: 13,800
0
Funds holding %
of 7,457 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
126% more call options, than puts
Call options by funds: $384M | Put options by funds: $170M
34% more first-time investments, than exits
New positions opened: 160 | Existing positions closed: 119
8% more funds holding in top 10
Funds holding in top 10: 13 [Q4 2024] → 14 (+1) [Q1 2025]
3% more repeat investments, than reductions
Existing positions increased: 727 | Existing positions reduced: 708
2% less capital invested
Capital invested by funds: $67.9B [Q4 2024] → $66.6B (-$1.27B) [Q1 2025]
1% less funds holding
Funds holding: 1,836 [Q4 2024] → 1,816 (-20) [Q1 2025]
1.94% less ownership
Funds ownership: 92.4% [Q4 2024] → 90.46% (-1.94%) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$165
1%
upside
Avg. target
$182
11%
upside
High target
$210
29%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Piper Sandler David Westenberg 46% 1-year accuracy 21 / 46 met price target | 29%upside $210 | Overweight Maintained | 12 May 2025 |
UBS Andrea Alfonso 100% 1-year accuracy 2 / 2 met price target | 4%upside $170 | Neutral Maintained | 7 May 2025 |
Stifel Jonathan Block 32% 1-year accuracy 6 / 19 met price target | 1%upside $165 | Buy Maintained | 14 Apr 2025 |
Financial journalist opinion
Based on 24 articles about ZTS published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Wall Street Analysts Think Zoetis (ZTS) Could Surge 26.18%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
2 days ago
Zoetis to Participate in Upcoming Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. BNP Paribas Animal Health Day on May 22, 2025 at 1:00 p.m. ET Stifel 2025 Jaws and Paws Conference on May 29, 2025 at 9:10 a.m. ET William Blair 45th Annual Growth Stock Conference on June 3, 2025 at 10:40 a.m. CT Investors and other interested parties can access live audio webcasts of the presentations by visiting http://invest.
Neutral
CNBC Television
1 week ago
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Positive
Seeking Alpha
1 week ago
Zoetis' Q1: Market Overreaction Or Justified Drop?
The market did not like Zoetis Inc. earnings despite strong growth and the evidence that Zoetis is becoming a better business. Buybacks continued throughout the quarter and Zoetis is a good example of how consistent buybacks can become significant over long periods. Despite competitive pressures, key franchises like Simparica and Apoquel continue to grow. This portrays one of the attractive characteristics of the animal health industry.
Neutral
Seeking Alpha
1 week ago
Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)
Zoetis shares have underperformed, losing 8% over the past year, but recent solid earnings and guidance suggest shares are nearer to fair value, shifting my stance from "sell" to "hold.". The company reported $1.48 EPS, beating estimates, with 9% organic growth despite foreign exchange headwinds; US dollar weakness should boost future results. Zoetis maintains a strong balance sheet, with $1.7 billion cash and $6.6 billion debt, supporting shareholder returns through buybacks and dividends.
Positive
CNBC Television
1 week ago
Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck
Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.
Neutral
Seeking Alpha
1 week ago
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazquez - William Blair Chris Schott - JPMorgan Navann Ty - BNP Paribas Daniel Clark - Leerink Partners Operator Welcome to the First Quarter 2025 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
Positive
Zacks Investment Research
1 week ago
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
Positive
Zacks Investment Research
1 week ago
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Positive
Zacks Investment Research
1 week ago
Zoetis (ZTS) Surpasses Q1 Earnings and Revenue Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $1.38 per share a year ago.
Charts implemented using Lightweight Charts™